Abnormal MDMX degradation in tumor cells due to ARF deficiency

X. Li, Daniele Gilkes, B. Li, Q. Cheng, D. Pernazza, H. Lawrence, N. Lawrence, J. Chen

Research output: Contribution to journalArticle

Abstract

MDMX is a heterodimeric partner of MDM2 and a critical regulator of p53. The MDMX level is generally elevated in tumors with wild-type p53 and contributes to p53 inactivation. MDMX degradation is controlled in part by MDM2-mediated ubiquitination. Here, we show that MDMX turnover is highly responsive to changes in MDM2 level in non-transformed cells, but not in tumor cells. We found that loss of alternate reading frame (ARF) expression, which occurs in most tumors with wild-type p53, significantly reduces MDMX sensitivity to MDM2. Restoration of ARF expression in tumor cells enables MDM2 to degrade MDMX in a dose-dependent manner. ARF binds to MDM2 and stimulates a second-site interaction between the central region of MDM2 and MDMX, and thus increases MDMX-MDM2 binding and MDMX ubiquitination. These results reveal an important abnormality in the p53-regulatory pathway as a consequence of ARF deficiency. Loss of ARF during tumor development not only prevents p53 stabilization by proliferative stress but also causes accumulation of MDMX that compromises p53 activity. This phenomenon may reduce the clinical efficacy of MDM2-specific inhibitors by preventing MDMX downregulation.

Original languageEnglish (US)
Pages (from-to)3721-3732
Number of pages12
JournalOncogene
Volume31
Issue number32
DOIs
StatePublished - Aug 9 2012
Externally publishedYes

Fingerprint

Reading Frames
Ubiquitination
Neoplasms
Down-Regulation

Keywords

  • ARF
  • MDM2
  • MDMX
  • nutlin
  • p53
  • ubiquitination

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Li, X., Gilkes, D., Li, B., Cheng, Q., Pernazza, D., Lawrence, H., ... Chen, J. (2012). Abnormal MDMX degradation in tumor cells due to ARF deficiency. Oncogene, 31(32), 3721-3732. https://doi.org/10.1038/onc.2011.534

Abnormal MDMX degradation in tumor cells due to ARF deficiency. / Li, X.; Gilkes, Daniele; Li, B.; Cheng, Q.; Pernazza, D.; Lawrence, H.; Lawrence, N.; Chen, J.

In: Oncogene, Vol. 31, No. 32, 09.08.2012, p. 3721-3732.

Research output: Contribution to journalArticle

Li, X, Gilkes, D, Li, B, Cheng, Q, Pernazza, D, Lawrence, H, Lawrence, N & Chen, J 2012, 'Abnormal MDMX degradation in tumor cells due to ARF deficiency', Oncogene, vol. 31, no. 32, pp. 3721-3732. https://doi.org/10.1038/onc.2011.534
Li X, Gilkes D, Li B, Cheng Q, Pernazza D, Lawrence H et al. Abnormal MDMX degradation in tumor cells due to ARF deficiency. Oncogene. 2012 Aug 9;31(32):3721-3732. https://doi.org/10.1038/onc.2011.534
Li, X. ; Gilkes, Daniele ; Li, B. ; Cheng, Q. ; Pernazza, D. ; Lawrence, H. ; Lawrence, N. ; Chen, J. / Abnormal MDMX degradation in tumor cells due to ARF deficiency. In: Oncogene. 2012 ; Vol. 31, No. 32. pp. 3721-3732.
@article{e791a30d8d4941799c8167ccdda52d86,
title = "Abnormal MDMX degradation in tumor cells due to ARF deficiency",
abstract = "MDMX is a heterodimeric partner of MDM2 and a critical regulator of p53. The MDMX level is generally elevated in tumors with wild-type p53 and contributes to p53 inactivation. MDMX degradation is controlled in part by MDM2-mediated ubiquitination. Here, we show that MDMX turnover is highly responsive to changes in MDM2 level in non-transformed cells, but not in tumor cells. We found that loss of alternate reading frame (ARF) expression, which occurs in most tumors with wild-type p53, significantly reduces MDMX sensitivity to MDM2. Restoration of ARF expression in tumor cells enables MDM2 to degrade MDMX in a dose-dependent manner. ARF binds to MDM2 and stimulates a second-site interaction between the central region of MDM2 and MDMX, and thus increases MDMX-MDM2 binding and MDMX ubiquitination. These results reveal an important abnormality in the p53-regulatory pathway as a consequence of ARF deficiency. Loss of ARF during tumor development not only prevents p53 stabilization by proliferative stress but also causes accumulation of MDMX that compromises p53 activity. This phenomenon may reduce the clinical efficacy of MDM2-specific inhibitors by preventing MDMX downregulation.",
keywords = "ARF, MDM2, MDMX, nutlin, p53, ubiquitination",
author = "X. Li and Daniele Gilkes and B. Li and Q. Cheng and D. Pernazza and H. Lawrence and N. Lawrence and J. Chen",
year = "2012",
month = "8",
day = "9",
doi = "10.1038/onc.2011.534",
language = "English (US)",
volume = "31",
pages = "3721--3732",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "32",

}

TY - JOUR

T1 - Abnormal MDMX degradation in tumor cells due to ARF deficiency

AU - Li, X.

AU - Gilkes, Daniele

AU - Li, B.

AU - Cheng, Q.

AU - Pernazza, D.

AU - Lawrence, H.

AU - Lawrence, N.

AU - Chen, J.

PY - 2012/8/9

Y1 - 2012/8/9

N2 - MDMX is a heterodimeric partner of MDM2 and a critical regulator of p53. The MDMX level is generally elevated in tumors with wild-type p53 and contributes to p53 inactivation. MDMX degradation is controlled in part by MDM2-mediated ubiquitination. Here, we show that MDMX turnover is highly responsive to changes in MDM2 level in non-transformed cells, but not in tumor cells. We found that loss of alternate reading frame (ARF) expression, which occurs in most tumors with wild-type p53, significantly reduces MDMX sensitivity to MDM2. Restoration of ARF expression in tumor cells enables MDM2 to degrade MDMX in a dose-dependent manner. ARF binds to MDM2 and stimulates a second-site interaction between the central region of MDM2 and MDMX, and thus increases MDMX-MDM2 binding and MDMX ubiquitination. These results reveal an important abnormality in the p53-regulatory pathway as a consequence of ARF deficiency. Loss of ARF during tumor development not only prevents p53 stabilization by proliferative stress but also causes accumulation of MDMX that compromises p53 activity. This phenomenon may reduce the clinical efficacy of MDM2-specific inhibitors by preventing MDMX downregulation.

AB - MDMX is a heterodimeric partner of MDM2 and a critical regulator of p53. The MDMX level is generally elevated in tumors with wild-type p53 and contributes to p53 inactivation. MDMX degradation is controlled in part by MDM2-mediated ubiquitination. Here, we show that MDMX turnover is highly responsive to changes in MDM2 level in non-transformed cells, but not in tumor cells. We found that loss of alternate reading frame (ARF) expression, which occurs in most tumors with wild-type p53, significantly reduces MDMX sensitivity to MDM2. Restoration of ARF expression in tumor cells enables MDM2 to degrade MDMX in a dose-dependent manner. ARF binds to MDM2 and stimulates a second-site interaction between the central region of MDM2 and MDMX, and thus increases MDMX-MDM2 binding and MDMX ubiquitination. These results reveal an important abnormality in the p53-regulatory pathway as a consequence of ARF deficiency. Loss of ARF during tumor development not only prevents p53 stabilization by proliferative stress but also causes accumulation of MDMX that compromises p53 activity. This phenomenon may reduce the clinical efficacy of MDM2-specific inhibitors by preventing MDMX downregulation.

KW - ARF

KW - MDM2

KW - MDMX

KW - nutlin

KW - p53

KW - ubiquitination

UR - http://www.scopus.com/inward/record.url?scp=84864952738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864952738&partnerID=8YFLogxK

U2 - 10.1038/onc.2011.534

DO - 10.1038/onc.2011.534

M3 - Article

C2 - 22120712

AN - SCOPUS:84864952738

VL - 31

SP - 3721

EP - 3732

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 32

ER -